Aydin, Semra http://orcid.org/0000-0001-7393-9690
Passera, Roberto
Scaldaferri, Matilde
Dellacasa, Chiara Maria
Poggiu, Marco
Cattel, Francesco
Zallio, Francesco
Brunello, Lucia
Giaccone, Luisa
Dogliotti, Irene
Busca, Alessandro
Article History
Received: 19 April 2022
Revised: 20 July 2022
Accepted: 20 July 2022
First Online: 9 August 2022
Declarations
:
: A.B. has received honoraria from Gilead Sciences, Merck, Pfizer Pharmaceuticals and Jazz Pharmaceuticals; he has been speaker for Gilead Sciences, Merck, Pfizer Pharmaceuticals, DiaSorin, GSK, Basilea and Novartis; he has been part of an Advisory Board of Takeda, GILEAD and Pfizer. The remaining authors declare that there are no competing interests to declare.
: Before starting sorafenib treatment individual approval by the Hospital Commission for Off Label Use of Drugs was obtained and personal informed consent for off label treatment signed by each patient. According to Italian law (Italian Drugs Agency-AIFA, Guidelines for Observational Studies, 20 March 2008), no formal Institutional Ethic Committee (IEC) approval was required. The study was performed in accordance with the principles stated in the Declaration of Helsinki.
: All authors have read, understood and approved the authorship agreement.